Andy I'm asking your opinion on one query. If multikane only works on those who had not received chemo wouldn't that mean that those, who today, had recieved chemo cannot receive multikane. However, in the future all those who plan on recieving chemo will, instead, just use multikane. Effectively bringing that 60% endpoint in the same category as the current 40% endpoint that passed? I hope I worded that in a way that makese sense.
Scott, it is an excellent question. I think your assumption could materialize although it is too early to tell.
Remember clinical trial is just the beginning of the game. Once MK will be used in practice, there will be more additional knowledge about it works. If it works very well with significant tumor reduction benefit, it is absolutely possible that it might change the choice of subsequent treatment. Remember in phase 2, some patients had complete tumor remission and refused surgery, and they were still alive many years after the treatment.
MK is non-toxic and immunotherapy is getting more and more popular, so it is well possible that patients will insist on using it first before other toxic / painful conventional treatments.
You left out the minor detail that the trial failed its only primary endpoint. The company disclosed no actual data on its data-dredging exercise. CEO hilariously (and falsely) claiming that they can't disclose data due to "journals" lol!
Thanks Andy for your work on another one of your excellent articles. And it is really fair of you to note that you did predict that there was a possible grayzone and that's where we are. And thanks to the good work of you and frugal I'm staying long and strong. Just shifting my time frames a bit. Your work is much appreciated.
Fortunately it’s a good grey scenario. Multikine works well on a large part of population and is confirmed to be non-toxic. There is no way the FDA will not approve such a drug.
As you said, we need to adjust the timeframe. PPS does not matter now as Cel Sci has enough cash. What matters at the end is Multikine gets to the market, Cel Sci get bought out by a big pharma so Multikine can be used for more indications.
Andy I'm asking your opinion on one query. If multikane only works on those who had not received chemo wouldn't that mean that those, who today, had recieved chemo cannot receive multikane. However, in the future all those who plan on recieving chemo will, instead, just use multikane. Effectively bringing that 60% endpoint in the same category as the current 40% endpoint that passed? I hope I worded that in a way that makese sense.
Scott, it is an excellent question. I think your assumption could materialize although it is too early to tell.
Remember clinical trial is just the beginning of the game. Once MK will be used in practice, there will be more additional knowledge about it works. If it works very well with significant tumor reduction benefit, it is absolutely possible that it might change the choice of subsequent treatment. Remember in phase 2, some patients had complete tumor remission and refused surgery, and they were still alive many years after the treatment.
MK is non-toxic and immunotherapy is getting more and more popular, so it is well possible that patients will insist on using it first before other toxic / painful conventional treatments.
You left out the minor detail that the trial failed its only primary endpoint. The company disclosed no actual data on its data-dredging exercise. CEO hilariously (and falsely) claiming that they can't disclose data due to "journals" lol!
LOL, they just got a pile of data. That’s why they did not have time to disclose. It will come soon.
Thanks Andy for your work on another one of your excellent articles. And it is really fair of you to note that you did predict that there was a possible grayzone and that's where we are. And thanks to the good work of you and frugal I'm staying long and strong. Just shifting my time frames a bit. Your work is much appreciated.
Thank you Chris.
Fortunately it’s a good grey scenario. Multikine works well on a large part of population and is confirmed to be non-toxic. There is no way the FDA will not approve such a drug.
As you said, we need to adjust the timeframe. PPS does not matter now as Cel Sci has enough cash. What matters at the end is Multikine gets to the market, Cel Sci get bought out by a big pharma so Multikine can be used for more indications.
Take care
'Potential secondary benefits (e.g. tumor reduction, quality of life) to come', when is this coming ?
It will be included in the scientific publications. I have no view on the timing.